Analyst Price Target is $5.00
▲ +145.10% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CytoMed Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 145.10% upside from the last price of $2.04.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in CytoMed Therapeutics. This Buy consensus rating has held steady for over two years.
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. It has research collaboration agreement with Sengkang General Hospital Pte Ltd to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (UC-MSCs) to treat cartilage injury. The company was incorporated in 2018 and is headquartered in Singapore.
Read More
